Volibo 0.2 mg
| SKU | 1392 |
|---|---|
| Generic For | Voglitor |
| Strength | 0.2mg |
| Manufacturer | Sun Pharma |
| Active Ingredient | Voglibose |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 0.90 | US$ 27.00 | |||
|
|||||
| 60 Tablet/s | US$ 0.63 | US$ 37.8030%US$ 54.00 | |||
|
|||||
| 90 Tablet/s | US$ 0.52 | US$ 46.9842%US$ 81.00 | |||
|
|||||
Volibo 0.2 mg (Voglibose) – Affordable Voglitor Alternative
Volibo 0.2 mg is an anti-glycaemic drug-containing Voglibose as the active ingredient. Voglibose belongs to a class of drugs known as an alpha-glucosidase inhibitor, which effectively controls high blood sugar levels in your body. Your doctor may recommend it if you have Type 2 diabetes. You may receive this treatment when other similar medicines or restricted diet regime is unable to control high blood sugar level. The medicine delays the absorption as well as digestion of dietary polysaccharides by reversibly inhibiting enzymes like maltose, sucrose, isomaltase, etc. This cause a reduction in postprandial hyperglycaemia.
In clinical trials, Volibo .2mg was proven extremely effective when using in combination with other anti-diabetic medicines. The drug found to reduce the blood sugar levels significantly. The medicine is effective for people whose blood sugar is not managed by other anti-diabetic medication. A doctor will be able to advise you whether the medicine is suitable for you or not. Usually, the anti-diabetic agent is safe and well tolerable for people with type 2 diabetes.
Always take medicine according to the doctor’s instructions. Depending on your response to the treatment, the doctor alters your dose. Your dose may increase or decrease depending on your condition. You should check with your doctor if you are not sure. Volibo 0.2mg should not be given to patients with known hypersensitivity to Voglibose or other inactive constituents. People are suffering from inflammatory bowel syndrome, diabetic ketoacidosis, colonic ulceration, partial intestinal obstruction, and chronic disorders associated with digestion and absorption. The anti-diabetic drug should be given with caution when used along with other anti-diabetic agents such as glucuronide, sulfonyl amide, sulfonylurea, and insulin preparations for improving insulin resistance.
Side Effects of Volibo .2mg
Research studies have shown that Volibo helps to control blood sugar in patients with type 2 Diabetes Mellitus. But the drug to causes side effects. Most common side effects of Volibo 0.2 mg are given below:
- Gastrointestinal tract - flatulence, bloating, abdominal pain, diarrhoea, abdominal fullness, and nausea
- Liver problems - hepatitis with severe cholestasis
- Central nervous system disorders - vomiting, nausea, and dizziness.
Let your physician know about your medical history as well as current physical status along with the medicines you have been using. This helps your physician in determining the best treatment for you.
What is Voglibose and what condition does it treat?
Voglibose is an alpha-glucosidase inhibitor used to manage type 2 diabetes mellitus by controlling blood sugar levels after meals. Volibo 0.2 mg contains this active ingredient and helps prevent sharp glucose spikes following carbohydrate consumption. This antidiabetic medication works alongside diet and exercise to improve glycemic control in diabetic patients. Unlike insulin or sulphonylureas, this diabetes tablet doesn't stimulate insulin production but instead slows carbohydrate digestion. Voglibose is particularly effective for postprandial hyperglycemia, making it a valuable option for blood sugar management in adult-onset diabetes.
How does Voglibose work in the body?
Voglibose functions by inhibiting alpha-glucosidase enzymes located in the small intestine lining. These enzymes normally break down complex carbohydrates into simple sugars for absorption. By blocking this enzymatic activity, Volibo 0.2 mg delays carbohydrate digestion and glucose absorption, preventing sudden blood sugar surges after eating. This mechanism makes it a unique antidiabetic agent that specifically targets postprandial glucose elevation. The delayed absorption means glucose enters the bloodstream more gradually, helping maintain steadier glycemic levels throughout the day. This alpha-glucosidase inhibitor doesn't cause hypoglycemia when used alone because it doesn't trigger insulin release.
How long does Volibo 0.2 mg take to work?
Volibo 0.2 mg begins working immediately after ingestion, with peak effects occurring within one to two hours when taken just before meals. This diabetes medication containing voglibose starts inhibiting carbohydrate breakdown as soon as food reaches your intestines. However, noticeable improvements in overall blood sugar control typically appear after several weeks of consistent use. Most patients observe better postprandial glucose readings within two to four weeks when combined with proper diet. The full therapeutic benefit of this alpha-glucosidase inhibitor develops gradually as your body adjusts to the controlled carbohydrate absorption pattern over the first month of treatment.
When and how should I take Volibo 0.2 mg?
Take Volibo 0.2 mg immediately before your first bite of each main meal, typically three times daily with breakfast, lunch, and dinner. Swallow the tablet whole with water or chew it just as you begin eating to ensure the voglibose is present when carbohydrates reach your intestines. Timing is crucial for this antidiabetic medication to effectively slow glucose absorption. If you skip a meal, omit that dose rather than taking it afterward. Your doctor may adjust your dosage based on blood sugar response. Always follow your healthcare provider's specific instructions regarding timing and frequency for optimal diabetes management.
Is Volibo 0.2 mg safe for long-term use?
Volibo 0.2 mg is generally considered safe for extended use in managing type 2 diabetes, with many patients taking voglibose for years as part of their ongoing treatment regimen. Long-term studies show this alpha-glucosidase inhibitor maintains its effectiveness without causing significant organ toxicity. Regular monitoring of blood sugar levels and periodic health assessments help ensure continued safety. Some patients experience gastrointestinal adaptation over time, with initial digestive side effects often diminishing after several weeks. The medicine doesn't exhaust pancreatic function or cause dependency, making it suitable for prolonged diabetes control when medically appropriate.
Can I take Volibo 0.2 mg with other medicines?
Volibo 0.2 mg can often be combined with other diabetes medications like metformin, sulphonylureas, or insulin to achieve better blood sugar control. However, certain interactions require attention: digestive enzymes and intestinal adsorbents may reduce voglibose effectiveness, while combining it with insulin or insulin secretagogues increases hypoglycemia risk. This antidiabetic medication generally doesn't interfere with blood pressure tablets, cholesterol-lowering drugs, or most antibiotics. Inform your healthcare provider about all medications, supplements, and herbal products you're taking. Your doctor can adjust dosages appropriately to prevent interactions and optimize your overall diabetes treatment plan.
How does Volibo 0.2 mg compare to similar medicines in its class?
Volibo 0.2 mg offers advantages over other alpha-glucosidase inhibitors like acarbose and miglitol through its potency and tolerability profile. Voglibose effectively controls postprandial glucose at lower doses compared to acarbose, often resulting in fewer gastrointestinal complaints. Unlike metformin, which works systemically, this diabetes medication acts locally in the intestines with minimal systemic absorption. It doesn't cause weight gain like insulin or sulphonylureas, making it suitable for overweight diabetic patients. The medicine specifically targets after-meal sugar spikes rather than fasting glucose, complementing other antidiabetic agents that address different aspects of glycemic control throughout the day.
Is the generic Voglibose as effective as branded versions?
Generic voglibose is therapeutically equivalent to branded versions like Volibo 0.2 mg, containing the identical active ingredient at the same strength and meeting rigorous quality standards. Pharmaceutical regulations require generics to demonstrate bioequivalence, meaning they deliver the same amount of medicine into the bloodstream at the same rate as brand-name products. The alpha-glucosidase inhibitor works identically regardless of manufacturer, providing the same blood sugar control and postprandial glucose management. Cost differences between generic and branded diabetes medications reflect marketing expenses rather than efficacy variations. Both options offer reliable antidiabetic treatment when sourced from licensed pharmacies.
Why do patients choose PremiumRxDrugs for Volibo 0.2 mg?
Patients select PremiumRxDrugs for their voglibose supply because of competitive pricing that makes diabetes management more affordable, especially for ongoing treatment. The pharmacy guarantees authentic Volibo 0.2 mg sourced directly from manufacturers, eliminating concerns about counterfeit antidiabetic medications. Convenient features like easy prescription management and straightforward reordering simplify chronic disease care. Discreet packaging respects patient privacy, while worldwide shipping with free delivery options ensures accessibility across the USA, UK, Australia, Canada, and beyond. With over ten years of service to the diabetes community, as a licensed pharmacy, we have built a reputation through consistent reliability, quality assurance, and customer-focused service.
What are the common side effects of Voglibose?
Voglibose commonly causes gastrointestinal side effects including flatulence, abdominal bloating, diarrhea, and stomach discomfort, particularly during the first few weeks of treatment. These digestive symptoms occur because undigested carbohydrates reach the colon where bacteria ferment them, producing gas. Most patients find these effects diminish as their bodies adapt to the alpha-glucosidase inhibitor. Less frequently, some people experience soft stools or increased bowel movements. Serious side effects are rare but may include liver enzyme elevations or intestinal obstruction in susceptible individuals. Starting with lower doses and gradually increasing helps minimize gastrointestinal discomfort while your digestive system adjusts.
Who should avoid taking Voglibose?
Voglibose should be avoided by individuals with inflammatory bowel disease, intestinal ulcers, or any condition causing chronic intestinal obstruction, as this alpha-glucosidase inhibitor can worsen these digestive disorders. People with severe kidney disease, liver cirrhosis, or diabetic ketoacidosis should not use this antidiabetic medication. It's contraindicated during pregnancy and breastfeeding due to insufficient safety data. Patients with hernias or those who've had abdominal surgery recently should exercise caution. Those allergic to voglibose or with malabsorption syndromes should avoid this diabetes treatment. Children and adolescents typically aren't prescribed this medicine as it's primarily studied in adults with type 2 diabetes.
Login
Sign Up
Login
Sign Up